0000899243-16-012693.txt : 20160204 0000899243-16-012693.hdr.sgml : 20160204 20160204173126 ACCESSION NUMBER: 0000899243-16-012693 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160202 FILED AS OF DATE: 20160204 DATE AS OF CHANGE: 20160204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2066960703 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levitsky Hyam CENTRAL INDEX KEY: 0001375792 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 161389494 MAIL ADDRESS: STREET 1: C/O ANTIGENICS INC. STREET 2: 162 FIFTH AVE., SUITE 900 CITY: NEW YORK STATE: NY ZIP: 10010 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-02-02 0 0001594864 Juno Therapeutics, Inc. JUNO 0001375792 Levitsky Hyam C/O 307 WESTLAKE AVENUE NORTH, SUITE 300 SEATTLE WA 98109 0 1 0 0 See Remarks Stock Option (Right to Buy) 24.50 2016-02-02 4 A 0 100000 0.00 A 2026-02-01 Common Stock 100000 100000 D 1/48 of the shares subject to the option become vested and exercisable on March 2, 2016 and 1/48 of the shares subject to the option shall vest monthly thereafter. Executive Vice President, Research and Chief Scientific Officer /s/ Zachary Hale, attorney-in-fact 2016-02-04